Our case illustrates that the strategy of co-administering pembrolizumab with an agent specifically targeting the IL-6 - Th-17 - IL-17 pathway, in this case, tocilizumab, in a patient with advanced melanoma and Crohn’s disease may result in significant anti-tumor effects while possibly preventing/delaying autoimmune consequences. The gene discussed is IL6; the disease is Crohn disease.